Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. is set to present a poster on their latest clinical trial results at the prestigious United European Gastroenterology Week 2024 in Vienna, showcasing their innovative DiffuSphere™ technology for targeted drug delivery. The company’s focus on developing extended-release treatments for areas with high unmet medical need, including their current Phase 1b/2a RESOLVE trial for eosinophilic esophagitis, highlights their commitment to transforming patient care with potentially safer and more effective therapies.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
